However, the most significant weight reduction typically occurs after the patient reaches higher therapeutic doses (5.0 mg or above) over several months of consistent use
Carrying excess weight places considerable strain on the cardiovascular system, joints, and overall metabolism
Medically, Zepbound is a type of drug called a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual-agonist that is engineered in a laboratory
As of 2023, it appears a company called Covisit (a division of Palatin) or Cosette Pharmaceuticals took on commercializationfiercepharma.com
[10] The logic: if the peptide declines with age and its gene expression profile favors tissue repair, restoration of youthful levels might restore youthful repair capacity
Is there a certain type of patient more at risk? History of depression, anxiety, eating disorders Perfectionist personalities Patients in life transitionsdivorce, job loss, etc